Company Profile for Acucela

Published: Oct 05, 2017

--(BUSINESS WIRE)--Acucela Inc., is a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Acucela’s development pipeline include drug candidates and therapeutics for the treatment of retinitis pigmentosa, proliferative diabetic retinopathy, diabetic macular edema, AMD, Stargardt disease, cataracts and presbyopia. The company is also developing a monitoring device for neovascular retinal diseases, to be used directly by patients.

Company:

Acucela Inc.

Headquarters Address:

Kasumigaseki Tokyu Building 4F,

3-7-1 Kasumigaseki, Chiyoda-ku,

Tokyo

Japan

Main Telephone:

1-206-805-8300

Website:

www.acucela.com

Type of Organization:

A subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596)

Industry:

Biotechnology, Medical Devices, Pharmaceutical

Key Executives:

CEO: Ryo Kubota, M.D., Ph.D.

Public Relations

Contact:

Michael Hasegawa

Phone:

+81-3-6550-8928

Email:

mhasegawa@acucela.com

Investor Relations

Contact:

John Gebhart

Phone:

+1-206-805-3972

Email:

jgebhart@acucela.com

Back to news